Apoptotic Effects of A Cisplatin and Eugenol Co-treatment of G361 Human Melanoma Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Eugenol (4-allyl-2-methoxyphenol) is a naturally occurring phenolic compound that is widely used in dentistry as a component of zinc oxide eugenol cement that is commonly applied to the mouth environment. Cisplatin is one of the most potent known anticancer agents and shows significant clinical activity against a variety of solid tumors. This study was undertaken to investigate the synergistic apoptotic effects of co-treatments with eugenol and cisplatin on human melanoma (G361) cells. To investigate whether this co-treatment efficiently reduces the viability of G361 cells compared with each single treatment, an MTT assay was conducted. The induction and augmentation of apoptosis were confirmed by DNA electrophoresis, Hoechst staining and an analysis of DNA hypoploidy. Western blot analysis and immunofluorescent staining were also performed to evaluate the expression levels and the translocation of apoptosis-related proteins following this co-treatment. Furthermore,proteasome activity and mitochondrial membrane potential (MMP) changes were also assayed. The results indicated that a co-treatment with eugenol and cisplatin induced multiple pathways and processes associated with an apoptotic response in G361 cells including nuclear condensation,DNA fragmentation, a reduction in MMP and proteasome activity, the increase and decrease of Bax and Bcl-2, a decreased DNA content, the release of cytochrome c into the cytosol, the translocation of AIF and DFF40 (CAD)into the nucleus, and the activation of caspase-9, caspase-7,caspase-3, PARP and DFF45 (ICAD). In contrast, separate treatments of 300 μM eugenol or 3 μM cisplatin for 24 h did not induce apoptosis. Our present data thus suggest that a combination therapy of eugenol and cisplatin is a potential treatment strategy for human melanoma.
Abstract
Eugenol (4-allyl-2-methoxyphenol) is a naturally occurring phenolic compound that is widely used in dentistry as a component of zinc oxide eugenol cement that is commonly applied to the mouth environment. Cisplatin is one of the most potent known anticancer agents and shows significant clinical activity against a variety of solid tumors. This study was undertaken to investigate the synergistic apoptotic effects of co-treatments with eugenol and cisplatin on human melanoma (G361) cells. To investigate whether this co-treatment efficiently reduces the viability of G361 cells compared with each single treatment, an MTT assay was conducted. The induction and augmentation of apoptosis were confirmed by DNA electrophoresis, Hoechst staining and an analysis of DNA hypoploidy. Western blot analysis and immunofluorescent staining were also performed to evaluate the expression levels and the translocation of apoptosis-related proteins following this co-treatment. Furthermore,proteasome activity and mitochondrial membrane potential (MMP) changes were also assayed. The results indicated that a co-treatment with eugenol and cisplatin induced multiple pathways and processes associated with an apoptotic response in G361 cells including nuclear condensation,DNA fragmentation, a reduction in MMP and proteasome activity, the increase and decrease of Bax and Bcl-2, a decreased DNA content, the release of cytochrome c into the cytosol, the translocation of AIF and DFF40 (CAD)into the nucleus, and the activation of caspase-9, caspase-7,caspase-3, PARP and DFF45 (ICAD). In contrast, separate treatments of 300 μM eugenol or 3 μM cisplatin for 24 h did not induce apoptosis. Our present data thus suggest that a combination therapy of eugenol and cisplatin is a potential treatment strategy for human melanoma.
참고문헌 (51)
- Acehan D, "Three-dimensional structure of the apoptosome: Implications for assembly, procaspase-9 binding, and activation", Mol Cell, 9, pp.423~432 (2002)
- Adhami VM, "Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both invitro and in vivo", Clin Cancer Res, 13, pp.1611~1619 (2007)
- Cheng AC, "Induction of apoptosis by Uncaria tomentosa through reactive oxygen species production, cytochrome c release, and caspases activation in human leukemia cells", Food Chem Toxicol, 45, pp.2206~2218 (2007)
- Cooley ME, "Cisplatin: a clinical review. Part I--Current uses of cisplatin and administration guidelines", Cancer Nurs, 17, pp.173~184 (1994)
- Dattner AM, "Herbal and complementary medicine in dermatology", Dermatol Clin, 22, pp.325~332 (2004)
- Daugas E, "Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis", FASEB J, 14, pp.729~739 (2000)
- Del Bello B, "Cisplatininduced apoptosis in melanoma cells: role of caspase-3 and caspase-7 in Apaf-1 proteolytic cleavage and in execution of the degradative phases", Ann N Y Acad Sci, 1010, pp.200~204 (2003)
- Drexler HC, "Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells", FASEB J, 14, pp.65~77 (2000)
- Fox SA, "Cisplatin and TNF-alpha downregulate transcription of BclxL in murine malignant mesothelioma cells", Biochem Biophys Res Commun, 337, pp.983~991 (2005)
- Gaqnon V, "Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol", Apoptosis, 13, pp.259~271 (2008)
- García-Berrocal JR, "The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear", Br J Pharmacol, 152, pp.1012~1020 (2007)
- Golab J, "Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice", Anticancer Res, 20, pp.1717~1721 (2000)
- Gonzalez VM, "Is cisplatininduced cell death always produced by apoptosis", Mol Pharmacol, 59, pp.657~663 (2001)
- Green DR, "Mitochondria and apoptosis. Science", 281, pp.1309~1312 (1998)
- Gross A, "BCL-2 family members and the mitochondria in apoptosis", Genes Dev, 13, pp.1899~1911 (1999)
- "IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, in Allyl Compounds, Aldehydes, Epoxides and Peroxides", pp.75~ (1985)
- Im SJ, "Effect of Radix Ginseng and Radix Trichosanthis on the melanogenesis", Biol Pharm Bull, 26, pp.849~853 (2003)
- Iwase M, "Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors", Int J Oncol, 31, pp.1141~1147 (2007)
- Kim HM, "Effect of Syzygium aromaticum extract on immediate hypersensitivity in rats", J Ethnopharmacol, 60, pp.125~131 (1998)
- Kim HM, "Antianaphylactic properties of eugenol", Pharmacol Res, 36, pp.475~480 (1997)
- Kim HM, "Magnoliae flos inhibits mast celldependent immediate-type allergic reactions", Pharmacol Res, 39, pp.107~111 (1999)
- Kim JH, "Early mitochondrial hyperpolarization and intracellular alkalinization in lactacystininduced apoptosis of retinal pigment epithelial cells", J Pharmacol Exp Ther, 305, pp.474~481 (2003)
- Kondo K, "Teratani N, Kan T, Shimada Y. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma", Surg Today, 36, pp.966~974 (2006)
- Kroemer G, "Mitochondrial control of apoptosis", Immunol Today, 18, pp.44~51 (1997)
- Lee KJ, "Inhibition of tumor invasion and metastasis by aqueous extract of the radix of Platycodon grandiflorum", Food Chem Toxicol, 44, pp.1890~1896 (2006)
- Lee SH, "Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer", Cancer Lett, 259, pp.39~49 (2008)
- Mai Z, "Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells", Mol Carcinog, 46, pp.534~542 (2007)
- Markowitz K, "Biologic properties of eugenol and zinc oxide-eugenol", Oral Surg Oral Med Oral Pathol, 73, pp.729~737 (1992)
- Marshansky V, "Proteasomes modu late balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells", J Immunol, 166, pp.3130~3142 (2001)
- Mohammad RM, "Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts", Cancer, 106, pp.1260~1268 (2006)
- Na HJ, "Tongkyutang inhibits mast cell-dependent allergic reactions and inflammatory cytokines secretion", Clin Chim Acta, 319, pp.35~41 (2002)
- Orlowski RZ, "The role of the ubiquitin-proteasome pathway in apoptosis", Cell Death Differ, 6, pp.303~313 (1999)
- Park HI, "Szygium aromaticum (L.) Merr. Et Perry (Myrtaceae) flower bud induces apoptosis of p815 mastocytoma cell line", Life Sci, 69, pp.553~566 (2001)
- Pisano C, "Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models", Ann Oncol, 18, pp.1500~1505 (2007)
- Porter AG, "Protein translocation in apoptosis", Trends Cell Biol, 9, pp.394~401 (1999)
- Satoh K, "Interaction between eugenol-related compounds and radicals", Anticancer Res, 18, pp.425~428 (1998)
- Seki K, "Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, 3 and -6 in osteosarcoma", Cancer Chemother Pharmacol, 45, pp.199~206 (2000)
- Shibuya H, "Induction of apoptosis and", or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins, 2003, pp.13, 457~464
- Shin BK, "suppression of L-histidine decarboxylase mRNA expression by methyleugenol", Biochem Biophys Res Commun, 232, pp.188~191 (1997)
- Song MQ, "Synergistic effect of oxymatrine and angiogenesis inhibitor NM-3 on modulating apoptosis in human gastric cancer cells", World J Gastroenterol, 13, pp.1788~1793 (2007)
- Susin SA, "Molecular characterization of mitochondrial apoptosis-inducing factor", Nature, 397, pp.441~446 (1999)
- Suzuki Y, "Eugenol-mediated superoxide generation and cytotoxicity in guinea pig neutrophils", Jpn J Pharmacol, 39, pp.381~386 (1985)
- Vinall RL, "Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and", or apoptosis, 2007, pp.13, 6204~6216
- Wagenknecht B, "Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release", J Neurochem, 75, pp.2288~2297 (2000)
- Wang G, "Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review)", Oncol Rep, 12, pp.955~965 (2004)
- Williams GT, "Programmed cell death: Apoptosis and oncogenesis", Cell, 65, pp.1097~1098 (1991)
- Wright SE, "Intravenous eugenol causes hemorrhagic lung edema in rats: proposed oxidant mechanisms", J Lab Clin Med, 125, pp.257~264 (1995)
- Yuan J, "Evolutionary conservation of a genetic pathway of programmed cell death", J Cell Biochem, 60, pp.4~11 (1996)
- Yde CW, "Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1", Int J Oncol, 29, pp.1397~1404 (2006)
- Zhou H, "The induction of cell cycle regulatory and DNA repair proteins in cisplatin-induced acute renal failure", Toxicol Appl Pharmacol, 200, pp.111~120 (2004)
- Zhu YP, "Chemistry, Pharmacology and Application. 1st ed", pp.1~3 (1996), Harwood Academic Publishers